Removing a blood clot from a large brain artery, then injecting the clot-dissolving drug tenecteplase into the artery resulted in stroke survivors being more likely to have better function 90 days after their stroke than those receiving standard clot removal, according to preliminary late-breaking science presented today at the American Stroke Association’s International Stroke Conference 2025.
Medical technology specialist avateramedical is restructuring through insolvency proceedings – Biotech Investments
EQS-News: avateramedical GmbH / Key word(s): Insolvency Medical technology specialist avateramedical is restructuring through insolvency proceedings 12.10.2023 / 14:45 CET/CEST The issuer is solely responsible